Giftify, Inc. Reports Surge in Pharmacy Retailer Gift Card Demand Following GLP-1 Medication Savings Initiative
Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving Solutions
Surge Driven by Ozempic and Zepbound Prescription Savings Opportunities Combined with Seasonal Health Product Purchases
SCHAUMBURG, IL, March 12, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ: GIFT) (the 'Company'), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced a significant increase in gift card sales following its announcement of a smart savings program for GLP-1 diabetes and weight loss medications.
CardCash.com, Giftify's secondary gift card exchange platform, experienced an overall 916% week-over-week increase in the face value of gift cards sold across major pharmacy retailers, including CVS and Walgreens. This surge follows the Company's recent announcement of innovative savings opportunities for consumers purchasing high-cost prescription medications such as Ozempic (semaglutide) from Novo Nordisk and Zepbound (tirzepatide) from Eli Lilly, in addition to increased consumer demand for seasonal cold and flu remedies and other winter health products.
'The response to our pharmacy gift card savings initiative has exceeded our expectations,' said Ketan Thakker, CEO of Giftify, Inc. 'This significant growth demonstrates the value proposition of our business model and validates our strategic expansion into the healthcare sector.'
To meet this growing demand, we have significantly increased our inventory levels:
CVS inventory levels grew by 120% year-over-year;
Walgreens inventory experienced a remarkable 736% increase.
This inventory expansion ensures CardCash can continue to meet consumer needs while maintaining competitive discount rates.
'Our latest promotional efforts have resonated strongly with consumers, leading to a measurable increase in sales activity,' said Carol Rosenblum, Marketing Manager at CardCash.com. 'We are committed to supporting our customers by not only offering savings on essential medications like Ozempic and Zepbound, but also ensuring convenient access to gift card solutions across our retail partners during this peak season for health-related product purchasing.'
The Company has placed increased emphasis on its pharmacy gift card program to address the growing critical need for improved preventive care and affordable access to newer treatment options. By providing practical tools to reduce prescription costs, CardCash.com supports broader healthcare accessibility while expanding Giftify's market reach.
About Giftify, Inc.
Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation's largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.
For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.
Press Releases may include forward-looking statements. In particular, the words 'believe,' 'may,' 'could,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'project,' 'propose,' 'plan,' 'intend,' and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company's ability identify a suitable business model for the corporation.
Investors Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
14 minutes ago
- Hamilton Spectator
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 29 in Pheonix, Arizona. Dr. Backus' presentation highlighted the importance of treatment adherence as a key requirement for achieving a clinically meaningful improvement in gait disability over 14 weeks of therapy and its sustained therapeutic effect well into 6 months after the end of treatment. The study results confirm controlled and real-world clinical evidence of PoNS Therapy's long-term benefits already reported in people with balance deficit due to traumatic brain injury (TBI). 'The results from this study were received with great interest as they provide the first clinical trial evidence of the long-term therapeutic benefits of PoNS Therapy for functional rehabilitation in the MS population,' stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. 'We were excited to engage with both US healthcare professionals and Canadian MS specialists and offer additional insights on the body of clinical and mechanistic evidence of PoNS Therapy's effect in MS. We are encouraged by the growing recognition of the importance of PoNS' direct effect on the central nervous system and its targeted mechanism of action as well as how it correlates with a lasting and sustained effect on gait rehabilitation, especially when comparing PoNS Therapy to other interventions limited to peripheral neuromuscular or transcutaneous stimulation.' CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers and appreciated the Company's relentless effort to engage with health insurance providers, viewing it as a much-needed endeavor to expand access to PoNS Therapy to all people with MS. 'We are excited by the positive conversations had at CMSC regarding both the therapeutic impact of the data presented and the recent announcement of reimbursement from the VA and out of network commercial payers for PoNS,' stated Dane Andreeff, Helius' President and Chief Executive Officer. 'We anticipate that the increase in reimbursement coverage will significantly lower the barrier to prescribe PoNS and allow for greater access to this important therapy.' About PoNS Therapeutic Experience Program (PoNSTEP) The PoNS Therapeutic Experience Program ('PoNSTEP') is a Helius-sponsored, open-label, observational, interventional multi-center outcome research study designed to assess adherence to on-label PoNS Therapy for improvement in gait deficits for patients with multiple sclerosis ('MS') in a real-world clinical setting. The study aims to understand better the relationship between adherence to on label (100-120 minute per day) PoNS Therapy, which combines the PoNS device with physical therapy, and the therapeutic outcome on gait deficit improvement over 14 weeks of study treatment, as measured by changes in the Dynamic Gait Index (DGI) scores. PoNS Therapy is applied in a supervised clinical setting for the first two weeks (Phase 1) and, independently, at home for the remaining 12 weeks (Phase 2). The study also includes a six-month no-treatment follow-up phase aimed at establishing the durability of the therapeutic effect (Phase 3). The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject's adherence to PoNS Therapy. The secondary endpoints are, among others, maintenance of improvement of gait and balance deficit over a 6-month timeframe and clinical global impression of change. The study was performed at six Centers of Excellence across the United States, including Neurology Center of New England in Foxboro (MA), the Shepherd Center in Atlanta (GA), Montefiore Medical Center ('Montefiore') in NY (NY), Oregon Health & Science University ('OHSU') in Portland (OR), MGH Institute of Health Professions in Boston (MA), NYU Langone Health in NY (NY), and recruited 43 MS participants with gait deficit. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit . About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit . Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the PoNSTEP study results, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or . The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip Taylor Gilmartin Group investorrelations@
Fox News
28 minutes ago
- Fox News
Medical experts warn 'Big Food' is fighting back against Ozempic with addictive items for sale
Ozempic and other weight-loss drugs may be cutting through "food noise," yet the junk food industry is only getting louder, some medical experts claim. "Ozempic is breaking the food addiction cycle – but Big Food isn't going down without a fight," Dr. Mark Hyman, an internationally recognized advocate for functional medicine, said in a recent Instagram post. "For decades, ultraprocessed foods have been engineered to hijack the brain's reward system – perfecting the 'bliss point' of sugar, salt and fat to keep people hooked," the physician also said. As Americans work to take hold of their health and wellness – and as the government cracks down on artificial food additives – the snack food industry appears to be evolving to outsmart both drugs and lifestyle changes, according to some observers. "Big Food isn't happy," Hyman continued, expressing his point of view. "Our food system is broken. It's built to create addictions, push ultraprocessed junk and profit off public health crises." Weight-loss and life coach Charles D'Angelo, based in St. Louis, Missouri, agreed with that assessment. "The food industry is one of many things evolving to outsmart our judgment sometimes," D'Angelo told Fox News Digital. "They are even outsmarting these medications and different health trends by engineering foods that bypass your hunger and can ultimately lead you to be more reactive than you otherwise would be." Fox News Digital reached out to Novo Nordisk, the manufacturer of Ozempic, for comment. Hyper-palatable foods (HPF) are designed with combinations of palatability-inducing ingredients, fat, sugar and carbohydrates that together enhance a food's deliciousness and produce an artificially rewarding eating experience, according to the National Institutes of Health (NIH). The Consumer Brands Association, based in Arlington, Virginia, represents the interests of the consumer-packaged goods (CPG) industry. "The makers of America's trusted household brands deliver safe products to consumers and innovate to provide them with healthier options," Sarah Gallo, senior vice president of product policy for the Consumer Brands Association, told Fox News Digital. "No industry is closer to the consumer than this one," she added. "For decades, food and beverage companies have taken their cues from consumers on what products they want in the marketplace to meet their dietary and health goals – whether it's options low in sugar, sodium and saturated fats, no artificial colors or low-carb, high-protein and high-fiber options." D'Angelo said that even without added ingredients, however, marketing campaigns often mislead consumers into purchasing and eating or drinking foods they think are healthful when they're not, D'Angelo said. "That's not nutrition. It's marketing." "They're not just selling junk food anymore," D'Angelo said. "How many things do you see when you go down the grocery store aisle that say high-protein or low-carb, but they're still ultraprocessed? And it's engineered to hook you. That's not nutrition. It's marketing." Gallo said her organization is aligned with the goal of radical transparency and aiding consumers in making informed choices. "The industry has been actively engaged in initiatives to improve nutritional information accessibility for over a decade," Gallo said. One initiative is Facts Up Front, a voluntary program that presents key nutritional information on the front of packaging, facilitating quick assessment by consumers. Additionally, the industry has introduced SmartLabel, allowing consumers to access detailed nutritional information via QR codes. For more Lifestyle articles, visit Gallo said the Consumer Brands Association "stands ready" to work with the federal government "to continue to ensure the analysis of safe ingredients and increase consumer transparency." She added, "It's also why we are working with Congress to ensure the [U.S. Food and Drug Administration] is properly resourced to carry out this important work and moving to mandatory notifications for new ingredients." "We need clarity, awareness and a complete shift in mindset to take back ownership of our choices." Still, D'Angelo said, misleading labels can give people a false sense of confidence in their personal choices. "I see how people are being conditioned subtly and repeatedly to trust marketing over their own inner signals, their own inner judgment," he said. "That's why we need more than just willpower or medications. We need clarity, awareness and a complete shift in mindset to take back ownership of our choices."
Business Wire
30 minutes ago
- Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About Uncomplicated Gonorrhea With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections, the World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the ten most critical global threats to public health. The bacterium Neisseria gonorrhoeae, which causes gonorrhea, has progressively developed resistance to most classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. About Zoliflodacin Zoliflodacin is an investigational first-in-class antibacterial that is administered in a single oral dose for the treatment of uncomplicated gonorrhea. The oral route of administration simplifies treatment by providing a convenient option for patients unable to receive an intramuscular injection. Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In in vitro studies, zoliflodacin demonstrated activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. In a pivotal Phase 3 clinical trial, zoliflodacin demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection with a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of 500mg ceftriaxone followed by 1g of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ('IST'), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ('GSK'). Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to ANORO ®, RELVAR ® and BREO ® are trademarks of the GSK group of companies. ZEVTERA ® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.
